<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9809">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05689710</url>
  </required_header>
  <id_info>
    <org_study_id>CARDIO_INO22</org_study_id>
    <nct_id>NCT05689710</nct_id>
  </id_info>
  <brief_title>The Effects of Inositol on Glucose Metabolism in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis</brief_title>
  <official_title>The Action of Inositols and Alpha-lactalbumin on Glucose Metabolism, Arterial Stiffness and Vascular Damage in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lo.Li.Pharma s.r.l</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lo.Li.Pharma s.r.l</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the effects of an oral supplementation based on inositols and&#xD;
      alpha-lactalbumin on principals metabolic parameters in patients with metabolic syndrome at&#xD;
      risk of cardiac fibrosis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2022</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>Four time points: changes in body weight (kg) from the baseline to 30, 90, 180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tryglicerides</measure>
    <time_frame>Four time points: changes in blood levels of tryglycerides from the baseline to 30, 90, 180 days</time_frame>
    <description>Plasmatic levels of tryglicerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension</measure>
    <time_frame>Four time points: changes in values of systolic and diastolic blood pressure from the baseline to 30, 90, 180 days</time_frame>
    <description>sphygmomanometer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Cardiac Fibrosis</condition>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Supplement with inositols and alpha-lactalbumin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inositol and alpha-lactalbumin</intervention_name>
    <description>The administration of an oral formulation based on inositol and alpha-lactalbumin (two sachets/day for 180 days)</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        At least 3 of the following inclusion criteria:&#xD;
&#xD;
          -  triglycerides levels ≥ 150 mg/dL&#xD;
&#xD;
          -  HDL ≤ 40 mg/dL&#xD;
&#xD;
          -  Fasting glycemia &gt; 100 mg/dL &lt;126 mg/dl&#xD;
&#xD;
          -  Systolic Pressure ≥ 130 mmHg or Diastolic pressure ≥ 85 mmHg&#xD;
&#xD;
          -  Hip circumference &gt; 102 cm in men or 88 cm in women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Davide Grassi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UOC Medicina Interna e Nefrologia P.O. AQ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudio Ferri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UOC Medicina Interna e Nefrologia P.O. AQ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Davide Grassi, MD</last_name>
    <phone>+393332123716</phone>
    <email>davide.grassi@cc.univaq.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>UOC Medicina Interna e Nefrologia P.O. AQ</name>
      <address>
        <city>L'Aquila</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davide Grassi, MD</last_name>
      <phone>333 2123716</phone>
      <email>davide.grassi@cc.univaq.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>December 23, 2022</study_first_submitted>
  <study_first_submitted_qc>January 10, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>January 18, 2023</last_update_submitted>
  <last_update_submitted_qc>January 18, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

